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Breast cancers enduring treatment with chemotherapy may be
enriched for cancer stem cells or tumor-initiating cells, which have
an enhanced capacity for self-renewal, tumor initiation, and/or
metastasis. Breast cancer cells that express the type I tyrosine
kinaselike orphan receptor ROR1 also may have such features.
Here we find that the expression of ROR1 increased in breast
cancer cells following treatment with chemotherapy, which also
enhanced expression of genes induced by the activation of Rho-
GTPases, Hippo-YAP/TAZ, or B lymphoma Mo-MLV insertion re-
gion 1 homolog (BMI1). Expression of ROR1 also enhanced the
capacity of breast cancer cells to invade Matrigel, form spheroids,
engraft in Rag2−/−γ−=−c mice, or survive treatment with paclitaxel.
Treatment of mice bearing breast cancer patient-derived xenografts
(PDXs) with the humanized anti-ROR1 monoclonal antibody cirmtu-
zumab repressed expression of genes associated with breast cancer
stemness, reduced activation of Rho-GTPases, Hippo-YAP/TAZ, or
BMI1, and impaired the capacity of breast cancer PDXs to metastasize
or reengraft Rag2−/−γ−=−c mice. Finally, treatment of PDX-bearing
mice with cirmtuzumab and paclitaxel was more effective than treat-
ment with either alone in eradicating breast cancer PDXs. These re-
sults indicate that targeting ROR1 may improve the response to
chemotherapy of patients with breast cancer.
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Breast cancers enduring chemotherapy may be enriched forcells with mesenchymal or stemness features, which can en-
able metastases or tumor relapse (1, 2). Epithelial cancer cells
that possess or acquire a mesenchymal phenotype have an en-
hanced capacity for migration and invasion, a process known as
epithelial-to-mesenchymal transition (EMT). In addition, EMT-
master-transcription factors (e.g., SNAI1) can enhance the
tumor-initiation capacity of cancer cells (3, 4). Cancer cells with
the capacity to regrow the tumor are called tumor-initiation cells
or cancer stem cells (CSCs); such cells have the capacity to self-
renew and/or differentiate and thereby repopulate the primary
tumor or establish metastatic tumors at distant sites (5). Recent
studies demonstrate that cancer cells may acquire stemness
features of CSCs in response to signals derived from the tumor
microenvironment and/or following treatment with chemother-
apy (5). If so, then targeting the CSC pathways that induce EMT
and/or that account for the acquisition of tumor stemness may be
more effective than strategies that only target existent CSCs (6).
CSCs with stemness features have the distinctive capacity
to form nonadherent cellular spheroids or engraft immune-
deficient mice (1, 7). Such cells have gene-expression signatures
that reflect their relatively high capacity for self-renewal and
ability to regenerate the entire tumor population (1). Notable is the
expression of B lymphoma Mo-MLV insertion region 1 homolog
(BMI1), a transcription repressor that belongs to the polycomb-
group family of proteins; high-level expression of BMI1 is associ-
ated with breast cancers that have a basal-like phenotype, which
typically is associated with relatively poor survival (8). BMI1 pro-
motes self-renewal and the acquisition of a tumor-initiation capacity
associated with CSCs (9–13). Moreover, BMI1 can promote ex-
pression of genes encoding ATP-binding cassette transporters, which
can enhance resistance to chemotherapy (3, 11).
Associated with cancer stemness is ROR1 (14), a type I ty-
rosine kinaselike orphan receptor, which is expressed by many
cancers but not by normal postpartum tissues (15, 16). Prior
studies found that breast cancers with high levels of ROR1
typically were poorly differentiated and expressed markers as-
sociated with EMT (15, 17). High-level breast cancer-cell ex-
pression of ROR1 associates with a relatively rapid relapse after
therapy and short survival (15, 17, 18). On the other hand, si-
lencing ROR1 could repress the expression of genes associated
with EMT and/or impair cancer-cell migration/invasion and
metastasis, indicating that ROR1 may play a role in inducing
stemness of breast cancer cells (17).
ROR1 can serve as a receptor for Wnt5a (19), which may be
expressed by tumor cells or by accessory cells within tumor mi-
croenvironment (20, 21). Wnt5a can induce noncanonical Wnt
signaling in chronic lymphocytic leukemia (CLL), leading to
activation of Rho-GTPases and enhanced tumor-cell migration,
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proliferation, and survival (22). Rho proteins, including RhoA,
Rac1, and cdc42, are expressed at high levels in breast cancer
cells relative to non-neoplastic cells of normal breast tissue (23).
Activation of Rho-GTPases can contribute to oncogenesis and
enhance the resistance to chemotherapy (24). In addition, acti-
vation of Rho-GTPases may induce Hippo-YAP/TAZ, which
helps maintain the stemness of embryonic or induced-pluripotent
stem cells and can promote the invasiveness, cytotoxic-drug re-
sistance, and the metastatic potential of cancer cells (25–29).
However, lacking is evidence that targeting ROR1 can repress
breast CSCs or inhibit the acquisition of stemness features by
breast cancer cells persisting after chemotherapy.
We examined for the expression of ROR1 in human breast cancer
cells of patients or mice engrafted with breast cancer patient-derived
xenografts (PDXs) before and after treatment with chemotherapy. In
addition, we examined whether the humanized anti-ROR1monoclonal
antibody (mAb) cirmtuzumab could block Wnt5a-induced ROR1
signaling and thereby manifest antitumor activity alone or in com-
bination with paclitaxel in mice bearing breast cancer PDXs.
Results
Breast Cancer Tissues After Chemotherapy Are Enriched for ROR1+
Cells. We obtained formalin-fixed paraffin-embedded biopsy
material from patients (n = 22) with invasive ductal breast ad-
enocarcinoma before (pre) and after (post) neoadjuvant che-
motherapy, consisting of four to six cycles of a combination of
docetaxel, doxorubicin or epirubicin, and/or cyclophosphamide. We
examined for the expression of ROR1 via immunohistochemistry (Fig.
1A and SI Appendix, Fig. S1A). Consistent with our previous findings
(15), ROR1 was detected on either estrogen receptor-positive (ER+)
or ER-negative (ER−) breast cancer cells. Here, we found breast
cancer expression of ROR1 increased in 14 (64%) of 22-matched
specimens, including ER+ or ER− breast cancer specimens. The
intensity of staining for ROR1 did not change with therapy in seven
(32%) cases (Fig. 1A and SI Appendix, Table S1). Only one post-
treatment specimen had a lower expression of ROR1 compared
with the matched pretreatment sample (SI Appendix, Table S1).
ROR1Hi Breast Cancer Cells Have Stemness Characteristics. To examine
the relevance of ROR1 in breast cancer, we established breast
cancer PDXs in Rag2−/−γ−=−c mice (SI Appendix, Table S2). The
PDXs retained the heterogeneity commonly found in primary
tumors, which typically have small proportions of cells with
stemness features. For example, only 0.6% or 6.5% of the tumor
cells in PDX1 or PDX4, respectively, had detectable aldehyde
dehydrogenase 1 (ALDH1) enzymatic activity, a commonly used
marker of CSCs (SI Appendix, Table S2) (30). Breast cancer PDX
cells with features of CSCs, such as the demonstration of ALDH1-
enzymatic activity (ALDH1+) or expression of CD44 with low-
level CD24 (CD44+/CD24Low cells), had higher levels of ROR1
than PDX cells of the same tumor lacking such CSC character-
istics, e.g., cells that were ALDH1Neg or that expressed high levels
Fig. 1. Chemotherapy enhances breast cancer expression of ROR1 and stemness. (A) Immunohistochemical staining of ROR1 in breast biopsy specimens obtained
from patients (n = 22) before (Pre) or after (Post) therapy with docetaxel/epirubicin ± cyclophosphamide. (Scale bar: 25 μM.) The table to the Right shows the
elevation of ROR1 on the breast cancer clinical specimens obtained from patients after chemotherapy treatment as assessed by Fisher’s exact test. (B) The graph
depicts the mean tumor growth of breast cancer PDXs in animals that did not receive treatment (black line, n = 7) or had received paclitaxel (red line, n = 5) on the
days indicated by the red arrows. (C) Lysates from PDX4 or PDX5 isolated from untreated mice (−) or mice treated with paclitaxel (+) were examined for ROR1 or
β-actin, which served to monitor the amount of protein per lane. The numbers below each lane are the ratios of band densities of ROR1 to β-actin normalized to
that for the PDXs isolated from untreated mice. (D and E) The histograms depict the average numbers of spheroids (D) or invading cells (E) from PDX4 or
PDX5 excised from mice that did not receive treatment (open bars, n = 3) or that were treated with paclitaxel (black bars, n = 3) ± standard error of the mean
(SEM). Representative photomicrographs to the Left of the histograms depict the spheroids or invasive cells of PDXs excised from untreated mice or from mice
that received paclitaxel. (Scale bar: 100 μm.) (F) Tumor cells were isolated from PDX4 or PDX5 mice that did not receive treatment (Untreated) or were treated
with paclitaxel (Paclitaxel) as indicated on the Left. Isolated tumor cells from each PDX were reimplanted into mice (n = 5), and the tumor incidence was recorded.
The Left provides representative photographs for tumors isolated from untreated mice or from mice that received paclitaxel. The frequency of tumorigenic cells
and the probability estimates are shown on the Right using the extreme limiting dilution analysis (ELDA) software.
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of both CD44 and CD24 (CD44+/CD24+ cells) (SI Appendix, Fig.
S1 B–D).
In tissue cultures, the PDX cells that had expressed high levels
of ROR1 had a greater capacity to form spheroids than PDX
cells of the same tumor that had low-to-undetectable ROR1 (SI
Appendix, Fig. S1 E–G). Furthermore, the tumor cells of each
PDX that had high-level ROR1 were more invasive in Matrigel
than tumor cells of the same PDX with low-to-undetectable
ROR1 (SI Appendix, Fig. S1H).
We implanted equal numbers of tumor cells from each PDX into
Rag2−/−γ−=−c mice and monitored the growth of secondary tumors.
When these secondary tumors reached ∼300 mm3 in size, we treated
the mice with paclitaxel at 13.4 mg/kg per day for five consecutive
days (Fig. 1B). The tumors derived from the PDX with high pro-
portions of ROR1+ cells (e.g., PDX4 or PDX5) regrew shortly after
therapy, in contrast to the tumors of mice engrafted with the PDX
that had few ROR1+ cells (e.g., PDX1 or PDX2, Fig. 1B).
We excised the tumors from mice bearing PDX4 or PDX5 and
examined the human breast cancer cells for the expression of
ROR1. We found the breast cancer PDXs excised from paclitaxel-
treated mice expressed higher levels of ROR1 than the PDXs
derived from the same tumor but excised from mice that did not
receive paclitaxel or the original PDXs (Fig. 1C). As noted in prior
studies (31), the tumors of mice treated with paclitaxel also had
higher proportions of ALDH1+ cells than the matched tumors of
untreated mice or the original PDX (SI Appendix, Fig. S1I). Fi-
nally, the PDX cells excised from mice treated with paclitaxel had
a greater capacity to form spheroids, invade Matrigel, or reengraft
Rag2−/−γ−=−c mice than the PDXs derived from the same tumor
but excised from mice that did not receive treatment or the
original PDX (Fig. 1 D–F).
We isolated breast cancer cells that had high levels of ROR1
(ROR1Hi) or low levels of ROR1 (ROR1Low) from PDX3, PDX4,
or PDX5 via flow cytometry using 4A5 (SI Appendix, Fig. S2A), a
mAb that binds an epitope of ROR1 that is distinct from that
bound by cirmtuzumab. ROR1Hi cells formed significantly greater
numbers of spheroids than ROR1Low cells, which formed few
spheroids or none at all (SI Appendix, Fig. S2B). Furthermore,
ROR1Hi cells were significantly more invasive in Matrigel
than ROR1Low cancer cells of the same tumor (SI Appendix,
Fig. S2C).
We performed tumorigenicity assays with limiting numbers of tu-
mor cells from PDX3, PDX4, or PDX5. Five hundred ROR1Hi cells
from each PDX could establish secondary PDXs in most mice (SI
Appendix, Fig. S2D). In contrast, the same numbers of ROR1Low cells
did not form tumors except in a few animals (SI Appendix, Fig. S2D).
Similarly, ALDH1+ or CD44+/CD24Low cells isolated from these
PDXs also had a significantly greater capacity to form secondary
PDXs than ALDH1Neg or CD44+/CD24+ cells of the same PDX (SI
Appendix, Table S3), in agreement with prior studies (1, 7, 30).
Expression of ROR1 Associates with Activation of Hippo-YAP/TAZ and
BMI1. We interrogated the PubMed Gene Expression Omnibus
(GEO) database (accession no. GSE87455) on HER2-negative
breast tumor biopsies obtained from patients before or after
treatment with four cycles of epirubicin plus docetaxel and
bevacizumab (2). Forty-three (76%) of the 57 post-treatment
biopsy specimens had higher levels of ROR1 than the matched
pretreatment tumor specimens. Similarly, 48 (84%) of the
matched tumor specimens had higher levels of ALDH1A1 after
therapy (SI Appendix, Fig. S3A). However, we did not observe a
significant difference in the levels of WNT5A between pre- and
post-treatment tumor samples (SI Appendix, Fig. S2A). Gene set
enrichment (GSE) analysis revealed that post-treatment breast
cancer cells had higher-level expression of genes associated with
the activation of Rho-GTPases, Hippo-YAP/TAZ, or BMI1 than
matched pretreatment tumor specimens (SI Appendix, Fig. S3B).
Compared with matched pretreatment breast cancer-biopsy speci-
mens, the breast cancer tissue obtained from patients after che-
motherapy expressed higher levels of genes associated with EMT,
CD44+/CD24Low CSCs, or mammosphere- (MS-) forming cells (SI
Appendix, Fig. S3B).
We segregated the pretreatment specimens (n = 122) of
GSE87455 into two subgroups based upon their relative ex-
pression of ROR1. Samples with ROR1 levels greater than the
median level expressed in all samples were designated as ROR1Hi
(n = 61), whereas tumor samples with lower ROR1 were desig-
nated as ROR1Low. The differences in gene expression between
matched post- and pretreatment specimens resembled those of
ROR1Hi versus ROR1Low breast cancers.
Of the 34,694 genes analyzed, we identified the 1,000 most
overexpressed and the 1,000 most underexpressed genes differ-
entially expressed in post-treatment versus pretreatment breast
cancer specimens or in ROR1Hi versus ROR1Low breast cancers.
Three-hundred-sixty-five of the 1,000 most overexpressed tran-
scripts after chemotherapy were among the 1,000 most overex-
pressed in ROR1Hi cancers relative to ROR1Low breast cancers
(e.g., ALDH1A1); only three of these 1,000 genes were among
the 1,000 most overexpressed in ROR1Low tumors relative to
ROR1Hi tumors (P < 0.0001, Fisher’s exact test). Conversely,
190 of the 1,000 most underrepresented transcripts after che-
motherapy were among the 1,000 most under-represented in
ROR1Hi breast cancers relative to ROR1Low breast cancers;
none of the 1,000 most under-represented genes after chemother-
apy were under-represented in ROR1Low tumors relative to ROR1Hi
cancers (P < 0.0001, Fisher’s exact test). GSE analysis revealed
that, relative to ROR1Low tumors, ROR1Hi tumors expressed
higher levels of genes associated with the activation of Rho-
GTPases (32, 33), Hippo-YAP/TAZ (34), BMI1 (35), or EMT
(36) (SI Appendix, Fig. S3C). Similar findings were observed for
samples described in the GSE21974 dataset (SI Appendix, Fig.
S3 D and E).
Moreover, compared with ROR1Low tumors, ROR1Hi breast
cancers also had higher expression of genes that were distinctively
overexpressed in embryonic stem cells, including those activated by
Oct4 or overlapping targets of Nanog, Oct4, and Sox2 (SI Appendix,
Table S4) (37). Finally, ROR1Hi breast cancers expressed higher
levels of genes that distinctively were overexpressed by CD44+
/CD24Low CSCs or MS-forming cells relative to CD44+/CD24+
non-CSCs or all tumor cells (1). Collectively, these analyses
indicate that therapy induced changes in gene expression that
more resembled those distinguishing ROR1Hi from ROR1Low
breast cancers, potentially reflecting treatment-related in-
creases in the proportions of ROR1+ cells and/or increased
expression of genes induced by ROR1 signaling rather than a
direct effect of chemotherapy per se.
Wnt5a Induces ROR1-Dependent Activation of Rho-GTPases, YAP/TAZ,
and BMI1.We extinguished ROR1 via CRISPR/Cas9 in the basal-
type breast cancer cell-line Hs578T (Fig. 2A). Exogenous Wnt5a
could induce activation of Rac1, RhoA, and cdc42 within 10 min
in wild-type Hs578T cells (wt-Hs578T) but not in ROR1−/−
Hs578T cells lacking ROR1 (ROR1−/− Hs578T) (Fig. 2A).
Treatment with Wnt5a also enhanced expression and nuclear
localization of YAP/TAZ in wt-Hs578T cells but not in ROR1−/−
Hs578T (Fig. 2 B and C).
Moreover, treatment with exogenous Wnt5a for 2 h enhanced
expression of BMI1 protein but not BMI1 messenger RNA in wt-
Hs578T cells but not ROR1−/− Hs578T cells (Fig. 2D and SI
Appendix, Fig. S4A), suggesting that Wnt5a induced increases in
BMI1 by interfering with its degradation.
We examined whether Wnt5a could induce Hs578T cells to ac-
tivate AKT, which prior studies found could inhibit proteasomal
degradation and promote accumulation of BMI1 (38). Wnt5a in-
duced AKT phosphorylation in wt-Hs578T cells but not in ROR1−/−
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Hs578T cells (Fig. 2D). On the other hand, treatment of wt-Hs578T
with siRNA specific for AKT or a small molecule inhibitor of AKT
(MK-2206) impaired the capacity of Wnt5a to induce activation of
AKT and inhibited the capacity of Wnt5a to enhance expression
of BMI1 (Fig. 2E and SI Appendix, Fig. S4B). Functionally,
ROR1−/− Hs578T cells formed significantly fewer spheroids than
wt-Hs578T cells (Fig. 2F). Also, treatment with exogenous Wnt5a
enhanced the capacity of wt-Hs578T cells but not ROR1−/−
Hs578T to invade Matrigel (Fig. 2G).
Cirmtuzumab Inhibits Wnt5a-Induced Activation of Rho-GTPases, Hippo-
YAP/TAZ, and BMI1 in Breast Cancer. We examined whether cirmtu-
zumab could inhibit Wnt5a-induced activation of Rho-GTPases,
Hippo-YAP/TAZ, or BMI1. Treatment of wt-Hs578T cells with
cirmtuzumab but not a human immunoglobulin G (hIgG) of ir-
relevant specificity, inhibited the capacity of exogenous Wnt5a to
induce activation of Rac1, RhoA, or cdc42 (Fig. 3A), nuclear lo-
calization of TAZ (Fig. 3 B and C), activation of AKT, or ex-
pression of BMI1 (Fig. 3 D and E). Furthermore, treatment with
cirmtuzumab but not control hIgG could block Wnt5a from en-
hancing the capacity of wt-Hs578T to form spheroids (Fig. 3F) or
invade Matrigel (Fig. 3G). Similarly, we found that breast cancer
PDX cells, which express Wnt5a (SI Appendix, Fig. S5A), had
significantly less nuclear TAZ after treatment for 4 h with cirm-
tuzumab than the same breast cancer cells treated with control
hIgG (SI Appendix, Fig. S5B). Moreover, cirmtuzumab but not
control hIgG could reduce the expression of BMI1 in breast
cancer PDX cells within 6 h (SI Appendix, Fig. S5C) and inhibit
the capacity of these cells to form spheroids or invade Matrigel (SI
Appendix, Fig. S5 D and E).
Cirmtuzumab Inhibits Reengraftment of Breast Cancer PDXs. We
evaluated the activity of cirmtuzumab on breast cancer PDXs in
vivo and found that biweekly intravenous infusions of cirmtu-
zumab (at 10 mg/kg) significantly suppressed the development
and growth of PDX tumors, including PDX3, which had low-
level expression of ROR1 (Fig. 4A and SI Appendix, Figs. S1E
and S5 F and G). Moreover, treatment of mice bearing breast
cancer PDXs with cirmtuzumab inhibited the development of
pulmonary metastases, significantly reducing the numbers of
metastatic foci from those noted in control hIgG-treated mice
(Fig. 4B).
We examined the transcriptomes of breast cancer PDXs ex-
cised from cirmtuzumab-treated mice (n = 4) versus control-
hIgG-treated mice (n = 4) and performed GSE analysis on the
RNA-seq data (GSE108632). Tumor cells isolated from breast
cancer PDXs of cirmtuzumab-treated mice expressed signifi-
cantly lower levels of genes associated with the activation of
Rho-GTPases, Hippo-YAP, BMI1, or EMT than cancer cells of
the same PDXs isolated from control-hIgG-treated mice (Fig. 4C
and SI Appendix, Fig. S5H). Moreover, tumors of cirmtuzumab-
treated mice also expressed significantly lower levels of genes
overexpressed by CD44+/CD24Low CSC or MS-forming cells (Fig.
4C) than did matched tumors of control-hIgG-treated mice. The
PDXs of cirmtuzumab-treated mice also had lower levels of ROR1,
activated Rho-GTPases, YAP/TAZ, or BMI1 than matched PDXs
excised from control-treated mice as assessed by immunoblot
analyses (Fig. 4D).
We examined PDX cells from control-treated or cirmtuzumab-
treated mice for their capacity to form secondary PDXs in
Rag2−/−γ−=−c mice. PDX cells isolated from cirmtuzumab-treated
mice were significantly less effective in forming secondary PDXs
Fig. 2. Wnt5a induces ROR1-dependent activation of Rho-GTPases, YAP/TAZ, and BMI1. (A) Immunoblot analyses for proteins as indicated on the right using
lysates prepared from Hs578T cells (Parental) or Hs578T knocked out for ROR1 (ROR1−/−) that were stimulated with Wnt5a for the times indicated. The
numbers below each lane are the ratios of the band densities of activated versus total GTPase, normalized with respect to cells treated without Wnt5a. (B)
Immunoblot analyses for proteins indicated on the right using lysates from parental or ROR1−/− Hs578T that were treated without (−) or with (+) Wnt5a as
indicated. The numbers below each lane represent the ratios of the band densities for each protein relative to that of β-actin, normalized with respect to cells
treated without Wnt5a. (C) Photomicrographs of parental (Top row) or ROR1−/− Hs578T cells (Bottom row) that were treated without or with Wnt5a as
indicated and then stained for YAP/TAZ and 4′,6-diamidino-2-phenylindole (DAPI) as indicated and then examined using confocal microscopy. (Scale bar:
20 μm.) The histogram to the Right of the photomicrographs provides the average percentages of YAP/TAZ located within the nuclei of the cells in each field
(n = 10, ±SEM). (D) Immunoblot analyses for proteins indicated on the right using lysates of parental or ROR1−/− Hs578T (as indicated on the Bottom) that
were treated with Wnt5a for the times indicated. The numbers below each lane are the ratios of band densities of BMI1 versus β-actin or pAKT versus total
AKT normalized to that of the sample collected at time 0. (E) Immunoblot analyses for proteins indicated on the right using lysates of Hs578T that had been
treated with control small interfering RNA (siRNA) or AKT-specific siRNA (AKT-siRNA) as indicated. The numbers below each lane are as in Fig. 3D. (F and G)
The histograms depict the average numbers of spheroids (F) or invasive cells (G) from parental or ROR1−/− Hs578T that were treated without or with Wnt5a in
triplicate ±SEM.
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than tumor cells of the same PDXs isolated from mice treated
with hIgG (Fig. 4E). Collectively, these data indicate that treat-
ment with cirmtuzumab inhibited the stemness of breast cancer
cells in vivo.
Treatment with Paclitaxel and Cirmtuzumab Achieves Greater Tumor
Clearance than Treatment with Either Alone. We treated PDX4- or
PDX5-bearing mice with cirmtuzumab (10 mg/kg), paclitaxel
(13.4 mg/kg) (39), or the combination of cirmtuzumab and pacli-
taxel. Treatment with cirmtuzumab and paclitaxel was significantly
more effective in reducing tumor volumes than treatment with
either cirmtuzumab or paclitaxel alone (Fig. 5A), each of which
significantly inhibited tumor growth relative to that of control-
treated animals. The tumor cells isolated from the PDXs of
mice treated with cirmtuzumab and paclitaxel had lower levels of
ROR1, activated Rho-GTPases, phosphorylated AKT, YAP/
TAZ, and BMI1 than did the tumor cells of the same PDXs ex-
cised from mice treated with paclitaxel alone (Fig. 5B). These data
demonstrate that the combination of cirmtuzumab and paclitaxel
had complementary antitumor activity.
We isolated tumor cells of PDXs that recurred in animals after
therapy and studied their relative capacity to form secondary
PDXs when engrafted in other immune-deficient mice. We found
that the tumor cells of the PDXs from mice treated with single-
agent paclitaxel readily developed secondary PDXs. However, the
tumor cells isolated from cirmtuzumab-treated mice were signifi-
cantly less effective in generating secondary PDXs than the tumor
cells isolated from animals treated with paclitaxel or hIgG.
However, none of the mice engrafted with tumor cells isolated
from mice treated with cirmtuzumab and paclitaxel developed
detectable tumors (Fig. 5C).
Discussion
Tumor recurrence following treatment with chemotherapy may
develop from chemotherapy-resistant preexisting CSCs or from
enduring cancer cells that subsequently acquire self-renewing
and/or tumor-initiating capacities, resulting from chemotherapy-
induced changes in the tumor or its microenvironment (niche sig-
naling) (40, 41). Here, we report that breast cancer cells surviving
chemotherapy expressed higher levels of ROR1, which was asso-
ciated with the activation of pathways induced by ROR1 signaling
(e.g., Hippo-YAP/TAZ and BMI1). Blocking ROR1 signaling with
the humanized anti-ROR1 mAb cirmtuzumab diminished the ac-
tivation of such pathways, the development of metastases, or the
capacity of cancer cells to persist after chemotherapy.
ROR1 signaling may contribute to the maintenance, self-
renewal, and drug resistance of cancer cells. Consistent with this
notion, we found that expression of genes associated with the
activation of Rho-GTPases was increased in breast cancer cells
with high levels of ROR1. Prior studies found that Rho-GTPase
signaling is altered in human breast tumors, and the elevated
expression and activation of Rho-GTPases correlates with tumor
progression, metastasis, and poor prognosis (23, 42). Further-
more, the activation of Rac1 may promote the survival of breast
cancer cells during radiation therapy (24).
High-level expression of ROR1 in primary breast cancer also
was associated with high levels of BMI1. Wnt5a/ROR1 signaling
may enhance the expression of BMI1 through its capacity to ac-
tivate AKT, which can phosphorylate BMI1 at three highly con-
served serine residues thereby reducing the rate of BMI1 protein
degradation (43). The resulting increase in BMI1 may account, in
part, for the enhanced capacity of ROR1Hi breast cancer cells to
initiate tumor growth, spread to distal sites, or resist the cytotoxic
effects of chemotherapy relative to breast cancer cells lacking
Fig. 3. Cirmtuzumab inhibits Wnt5a-induced ROR1-dependent activation of Rho-GTPases, YAP/TAZ, and BMI1. (A) Immunoblot analyses for proteins in-
dicated on the right using lysates of Hs578T that had been treated with a control hIgG or cirmtuzumab and then stimulated with Wnt5a for the times in-
dicated. The numbers below each lane are the ratios of the band densities of activated versus total GTPase, normalized with respect to the hIgG-treated cells
without Wnt5a. (B) Immunoblot analyses for proteins indicated on the right using lysates prepared from Hs578T cultured with cirmtuzumab or hIgG and then
treated without or with Wnt5a as indicated. The numbers below each lane represent the ratios of the band densities for each protein relative to that of
β-actin, normalized with respect to the hIgG-treated cells without Wnt5a. (C) Photomicrographs of Hs578T cultured overnight with cirmtuzumab or hIgG (as
indicted on the Left), then treated without or with Wnt5a for 4 h (as indicated), then stained for YAP/TAZ and DAPI (as indicated), and then examined via
confocal microscopy. (Scale bar: 20 μm.) The histogram to the Right of the photomicrographs provides the average percentages of YAP/TAZ located within the
nuclei of the cells in each field (n = 10, ±SEM). (D) Immunoblot analyses for proteins indicated on the right using lysates of Hs578T that had been treated
overnight with hIgG or cirmtuzumab and then treated without or with Wnt5a as indicated. The numbers below each lane are the ratios of band densities of
pAKT versus total AKT, normalized with respect to the hIgG-treated cells without Wnt5a. (E) Immunoblot analyses for proteins indicated on the right using
lysates of Hs578T that had been treated overnight with hIgG or cirmtuzumab and then treated with Wnt5a for the times indicated. The numbers below each
lane are the ratios of band densities of BMI1 versus β-actin, normalized with respect to the hIgG-treated cells without Wnt5a. (F and G) The bar graph depicts
the average numbers of spheroids (F) or invasive cells (G) from Hs578T cells that were incubated with hIgG or cirmtuzumab overnight and then treated with
or without Wnt5a in three separate culture wells ± SEM. The open bars indicate the number of spheroids detected during the first passage, whereas the
closed bars provide those of the second passage in three separate culture wells ± SEM.
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Fig. 4. Cirmtuzumab inhibits stemness of breast cancer PDXs. (A) The line graph depicts the mean tumor growth of each of PDX3, PDX4, and PDX5 over time (±SEM,
n = 6–8) for animals that did not receive treatment (black line) or that were treated with cirmtuzumab (red line) on the days indicated by the black arrows. One
asterisk indicates P < 0.05, and two asterisks indicate P < 0.01 using Student’s t Test. (B) Hematoxylin and eosin staining of lung tissue from a representative tumor-
bearing mouse engrafted with cells of PDX5 and treated with control hIgG or cirmtuzumab as indicated. A dashed-lined circle highlights metastatic foci. (Scale bar:
100 μm.) The scatter plot shows the average numbers of metastatic foci that were found in the lungs of each animal by the treatment group (±SEM, n = 6). (C)
Enrichment plots of genes associated with the activation of Rho-GTPases, Hippo-YAP, BMI1, or gene signature common on both CD44+/CD24Low cancer stem cells and
MS-forming cells in PDXs derived from PDX4 in mice treated with control hIgG versus cirmtuzumab as assessed via RNA sequencing (RNA-seq) (GSE108632). (D)
Immunoblot analyses for proteins indicated on the right using lysates prepared from PDX4 or PDX5 (as indicated on the Bottom) that were extirpated from mice
treated with control hIgG or cirmtuzumab as indicated. The numbers below each row are the ratios of band densities of activated versus total GTPase, pAKT versus
total AKT, BMI1, TAZ/YAP versus β-actin, or ROR1 versus β-actin, normalized to that of the first control sample. (E) Table providing the numbers ofmice that developed
tumors (numerator) versus the numbers of mice implanted (denominator) with cells from PDX3, PDX4, or PDX5 (as indicated in the left column), which were removed
from mice treated with either hIgG or cirmtuzumab (as indicated in the second column). For these experiments, mice were given varying numbers of tumor cells (as
indicated in the row below “cell number”). The frequencies of tumorigenic cells computed using ELDA software are provided in the penultimate right column. The P
values indicate the significance of the difference between the tumorigenic frequencies of tumor cells recovered from hIgG- versus cirmtuzumab-treated mice.
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ROR1. Conversely, inhibiting BMI1 with a small molecule PTC-
209 could enhance the sensitivity to chemotherapy and inhibit
metastases in squamous cell carcinoma or inhibit the growth of
colon cancer or breast cancer cells (12, 44).
The stemness of ROR1Hi breast cancer cells, in part, also could
be related to the activation of the Hippo-YAP/TAZ pathway.
Prior studies found that Rho-GTPase activation could induce
the Hippo-YAP/TAZ signaling, which could enhance the survival
and self-renewal of human-embryonic stem cells (25). Moreover,
coexpression of ROR1 with either FZD2 or FZD5 could induce
dephosphorylation YAP and the accumulation of TAZ, leading to
the activation of Hippo-YAP/TAZ signaling in HEK293A cells
(26). Similarly, we found the expression of ROR1 was associated
with the expression and nuclear localization of TAZ in primary
breast cancer cells and that Wnt5a could enhance nuclear accu-
mulation of TAZ in a ROR1-dependent manner. Furthermore,
the expression of ROR1 also could promote EMT, which could
enable epithelial breast cancer cells to migrate to distal sites (17).
The anti-ROR1 mAb cirmtuzumab may be effective in re-
versing cancer stemness. In a recently completed phase I trial
involving patients with relapse/refractory CLL, treatment with
cirmtuzumab inhibited leukemia-cell activation of Rho-GTPases
and ROR1-signaling (14). Moreover, treatment with cirmtuzu-
mab reversed the stemness gene expression signature of leuke-
mia cells noted before therapy (14). This is similar to what we
noted here in studies using mice engrafted with breast cancer
PDXs; treatment with cirmtuzumab but not control hIgG re-
pressed the expression of genes induced by the activation of
Rho-GTPases, Hippo-YAP/TAZ, or BMI1. Moreover, cirmtu-
zumab also repressed the expression of genes that were up-
regulated in EMT or CD44+/CD24Low CSC. Such reprogram-
ming was associated with impaired engraftment and reduced
capacity to develop metastases in immune-deficient mice.
Agents that inhibit cancer stemness may complement the an-
titumor activity of chemotherapy by eliminating drug-resistant
CSC or inhibiting the capacity of tumor cells to acquire features
of CSCs. We found that treatment of either ER+ or ER− breast
cancer PDXs with paclitaxel and cirmtuzumab had significantly
greater antitumor activity than treatment with either agent
alone. We speculate that cirmtuzumab or other agents that can
inhibit ROR1 signaling may improve the response to chemo-
therapy and enhance the survival of patients with breast cancer.
Materials and Methods
Breast Cancer Specimens. We used anonymized archived formalin-fixed paraffin-
embedded tumor tissues excised from patients (n = 22) with invasive ductal
carcinoma before and after treatment with four to six cycles of docetaxel (T) at
75 mg/m2 ± doxorubicin (A) at 75 mg/m2 or epirubicin (E) at 75 mg/m2 ± cy-
clophosphamide (C) at 600 mg/m2 (docetaxel/epirubicin/doxorubicin, doce-
taxel/doxorubicin/cyclophosphamide, docetaxel/epirubicin, or epirubicin and
cyclophosphamide ) at Sun Yat-set University Cancer Center, China. Each pa-
tient had a core needle biopsy or excisional biopsy before neoadjuvant che-
motherapy and had surgical resection of residual tumors after chemotherapy.
Primary breast tumor tissues used to generate PDXs were obtained from
biopsy material of patients with breast adenocarcinoma after they provided
written informed consent. Experiments involving these samples were ap-
proved by the Institutional Review Board of UC San Diego (HRPP090401) in
accordance with the Declaration of Helsinki.
Spheroid Formation Assay. Some 300–10,000 viable single cells were plated
on Ultra Low Attachment 6-well or 96-well plates (Corning Incorporated Life
Sciences) and cultured in MEGMTMmammary epithelial cell growth medium
(Lonza) with or without recombinant Wnt5a (R&D system) at 100 ng/mL for
1–3 wk. Spheroids with sizes greater than 100 μm were counted using an
inverted microscope (Nikon). A more detailed description of the reagents,
biochemistry assays, cellular analysis, and animal studies are provided in SI
Appendix, Materials and Methods.
ACKNOWLEDGMENTS. We thank Victoria Tripple for technical assistance in
the PDX studies and Dennis Young for flow-cytometry analysis and sorting.
We acknowledge the help of the Histology Core Laboratory for processing
tissue specimens, Dr. Nissi Varki for histology and immunohistochemistry
assessments, and the University of California San Diego Moores Cancer Cen-
ter Biorepository and Tissue Technology Shared Resource for PDX samples.
This paper was supported by the National Key Projects of Research and De-
velopment of China (Grant 2016YFC0904600), the National Natural Science
Foundation of China (Grant 81672912), the Science and Technology Foun-
dation of Shenzhen, China (Shenzhen Peacock Innovation Team Project,
Grant KQTD20140630100658078), the Breast Cancer Research Foundation
(Grant BCRF-17-120), National Institutes of Health Grant P01-CA081534,
and the California Institute for Regenerative Medicine.
Fig. 5. Cirmtuzumab and paclitaxel have complementary antitumor activity. (A) The line graph depicts the mean tumor growth of PDX4 or PDX5 over
time (±SEM, n = 8–10) in mice that were untreated (Control, black line) or treated with cirmtuzumab (purple line), paclitaxel (green line), or both (blue
line). (B) Immunoblot analyses for proteins indicated on the right using lysates prepared from PDX4 of mice that were not treated (Control) or treated
with cirmtuzumab, paclitaxel, or both as indicated. The numbers below each row are the ratios of band densities as in Fig. 4E. (C) Table providing the
numbers of mice that developed PDXs (numerator) versus the numbers of mice engrafted (denominator) with cells from either PDX4 or PDX5 (as indicated
in the top row) that were removed from mice treated with hIgG, cirmtuzumab, paclitaxel, or cirmtuzumab and paclitaxel (as indicated in the far left
column). The mice were given varying numbers of tumor cells as indicated in the row below the PDX designation. The Bottom provides a photograph of
representative tumors that developed in mice engrafted with tumor cells from PDX4 of mice that were untreated or treated with cirmtuzumab and/or
paclitaxel as indicated.
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